Tirzepatide: A GIP/GLP-1 Dual Receptor Agonist

Research summary. Tirzepatide is a synthetic 39-amino-acid peptide engineered as a unimolecular dual agonist at the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Developed by Eli Lilly and approved by the U.S. FDA as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management), it represents the first multi-receptor incretin agonist to achieve broad regulatory approval and a major advance over single-receptor GLP-1R agonists in head-to-head efficacy comparisons.

(Note: this catalogue uses the label "Tirzepatide-GLP2" for organisational reasons in the source material. Tirzepatide engages GIP and GLP-1 receptors rather than GLP-2; the naming convention reflects the catalogue's broader grouping of incretin-class peptides.)

Molecular profile

• Class: Long-acting GIP/GLP-1 dual receptor agonist
• Backbone: 39-amino-acid synthetic peptide based on native GIP with substitutions enabling GLP-1R cross-engagement
• Modification: C20 fatty diacid linker at lysine-20 supporting albumin binding for once-weekly dosing
• Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular weight: ~4813.5 g/mol
• PubChem CID: 156588324
• CAS Number: 2023788-19-2
• Brand names: Mounjaro (T2D), Zepbound (obesity)
• Half-life: ~5 days (subcutaneous)

The molecule's design draws more heavily on the GIP backbone than on GLP-1 — a notable design choice given that GLP-1R agonists were the established class. Tirzepatide has higher affinity for GIPR than for GLP-1R, although both receptors are engaged at clinically relevant concentrations.

Mechanism of action

Tirzepatide engages both incretin receptor systems:

GIPR engagement drives:

• Synergistic post-prandial insulin secretion alongside GLP-1
• Adipose-tissue effects, including increased adiponectin secretion
• CNS effects on hypothalamic feeding circuits
• Enhanced lipid handling and substrate oxidation

GLP-1R engagement drives:

• Glucose-dependent insulin secretion
• Suppression of post-prandial glucagon
• Slowing of gastric emptying
• Activation of central satiety circuits
• Beta-cell preservation through anti-apoptotic signalling

The two pathways are not redundant. GIPR engagement contributes uniquely to lipid metabolism, adiponectin elevation, and certain CNS effects, while GLP-1R engagement contributes uniquely to glucagon suppression and gastric emptying. The combination produces effects on body weight and HbA1c that exceed those of either single-receptor agonist class in head-to-head trials.

Clinical research highlights

Type 2 diabetes (SURPASS programme). SURPASS-2 (Frias et al., 2021) reported HbA1c reductions of 2.0–2.4% with tirzepatide 5/10/15 mg weekly, exceeding the active comparator semaglutide 1 mg in head-to-head comparison [1]. Subsequent SURPASS trials confirmed superiority across multiple background-therapy contexts.

Chronic weight management (SURMOUNT programme). SURMOUNT-1 (Jastreboff et al., 2022) reported approximately 21% mean body-weight reduction at 72 weeks at the highest dose (15 mg) in adults with overweight/obesity without diabetes — the largest mean weight reduction reported with any approved pharmacological agent in this population at the time of publication [2]. SURMOUNT-2 confirmed efficacy in adults with obesity and type 2 diabetes, with somewhat reduced (though still substantial) weight loss in this population.

Heart failure with preserved ejection fraction. SUMMIT trial reported improvements in heart-failure outcome measures with tirzepatide in patients with HFpEF and obesity.

Sleep apnoea. SURMOUNT-OSA reported improvements in apnoea-hypopnea index with tirzepatide in adults with obstructive sleep apnoea and obesity.

Adiponectin and the GIP arm

A distinctive feature of tirzepatide compared with single-target GLP-1R agonists is its substantial elevation of plasma adiponectin levels, attributed to GIPR engagement on adipose tissue. Adiponectin is associated with:

• Improved insulin sensitivity in skeletal muscle and liver
• Reduced adipose-tissue inflammation
• Increased HDL-cholesterol
• Reduced triglyceride levels
• Cardiovascular protective signalling

These effects contribute to the broader cardiometabolic benefit profile of tirzepatide beyond glycaemic control and weight management.

Tachyphylaxis considerations

Both GIPR and GLP-1R can undergo agonist-induced desensitisation with chronic exposure. The clinical relevance of this for tirzepatide is debated. The molecule's substantial GIPR activity has been argued by some researchers to actually require receptor desensitisation as a mechanistic component of its weight-loss effect — a hypothesis grounded in studies suggesting that GIPR antagonism (rather than agonism) can also produce weight loss in some preclinical contexts. This paradox remains an active area of investigation.

Position in the multi-receptor incretin landscape

Tirzepatide established the proof-of-concept for unimolecular multi-receptor incretin agonism. The class has since expanded:

• Cagrilintide: Long-acting amylin analogue (separate receptor system, frequently combined with semaglutide)
• Cotadutide, survodutide, pemvidutide: GLP-1/glucagon dual agonists
• Retatrutide: GIP/GLP-1/glucagon triple agonist (Phase 3)
• Maridebart cafraglutide (formerly MariTide): GLP-1R agonist / GIPR antagonist combination

Current status

Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). It is one of the most clinically validated peptide therapeutics introduced in recent years and represents a benchmark for multi-receptor incretin pharmacology.

Key takeaways for researchers

• Tirzepatide is a unimolecular GIP/GLP-1 dual receptor agonist, the first multi-receptor incretin agonist to achieve regulatory approval.
• It produces weight loss and HbA1c reductions exceeding those of single-target GLP-1R agonists in head-to-head trials.
• The GIP arm contributes uniquely to adiponectin elevation and adipose-tissue effects.
• Approved as Mounjaro (T2D) and Zepbound (obesity); also studied in HFpEF and obstructive sleep apnoea.
• Represents a benchmark molecule for the multi-receptor incretin class.

References

1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503–515.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216.

---

This article is provided for educational and research purposes only. While tirzepatide is FDA-approved for specific clinical indications under the brand names Mounjaro and Zepbound, research-grade tirzepatide supplied through research-peptide channels is not equivalent to a prescribed pharmaceutical and is not intended for human consumption. Approved use of tirzepatide should occur only under the direction of a qualified clinician and within an authorised supply chain. Research work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.